Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study.
Mountzios G, Lampaki S, Linardou H, Georgoulias V, Mavroudis D, Anevlavis S, Charpidou A, Lykka M, Spyratos D, Sarris EG, Somarakis A, Papista C, Glentis A, Nikolaou A, Paparepa Z, Papageorgiou F, Syrigos KN. Mountzios G, et al. Among authors: paparepa z. Future Oncol. 2025 Jan 9:1-16. doi: 10.1080/14796694.2024.2442295. Online ahead of print. Future Oncol. 2025. PMID: 39785129
Clinical Outcomes Beyond 1L EGFR-TKI Progression in mNSCLC: Final Results of the Real-World Study 'LUNGFUL'.
Mountzios G, Koumarianou A, Linardou H, Boutis A, Mavroudis D, Samantas E, Korantzis I, Athanasiadis E, Fergadis EG, Lampaki S, Georgoulias V, Baka S, Karamouzis MV, Boukovinas I, Andreadis C, Rapti A, Koulouris N, Pentheroudakis G, Froudarakis ME, Somarakis A, Anastasopoulou E, Karadimou A, Papageorgiou F, Paparepa Z, Nikolaou A, Papista C, Syrigos KN. Mountzios G, et al. Among authors: paparepa z. Anticancer Res. 2023 May;43(5):2243-2258. doi: 10.21873/anticanres.16388. Anticancer Res. 2023. PMID: 37097667
Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece.
Lampaki S, Mountzios G, Georgoulias V, Rapti A, Xanthakis I, Baka S, Mavroudis D, Samantas E, Athanasiadis E, Zagouri F, Charpidou A, Somarakis A, Papista C, Nikolaou A, Anastasopoulou E, Paparepa Z, Syrigos KN. Lampaki S, et al. Among authors: paparepa z. Future Oncol. 2022 Sep;18(28):3151-3164. doi: 10.2217/fon-2022-0386. Epub 2022 Aug 5. Future Oncol. 2022. PMID: 35929414
A Real-World, Observational, Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The 'LUNGFUL' Study.
Mountzios G, Koumarianou A, Bokas A, Mavroudis D, Samantas E, Fergadis EG, Linardou H, Katsaounis P, Athanasiadis E, Karamouzis MV, Pentheroudakis G, Lampaki S, Froudarakis ME, Perdikouri EA, Somarakis A, Papageorgiou F, Paparepa Z, Nikolaou A, Syrigos KN. Mountzios G, et al. Among authors: paparepa z. Cancers (Basel). 2021 Jun 25;13(13):3172. doi: 10.3390/cancers13133172. Cancers (Basel). 2021. PMID: 34202063 Free PMC article.